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Type 2 diabetes mellitus (T2DM) is a common complication of obesity. Here, we have shown that activation of the IgG receptor
FcγRIIB in endothelium by hyposialylated IgG plays an important role in obesity-induced insulin resistance. Despite becoming
obese on a high-fat diet (HFD), mice lacking FcγRIIB globally or selectively in endothelium were protected from insulin
resistance as a result of the preservation of insulin delivery to skeletal muscle and resulting maintenance of muscle glucose
disposal. IgG transfer in IgG-deficient mice implicated IgG as the pathogenetic ligand for endothelial FcγRIIB in obesityinduced insulin resistance. Moreover, IgG transferred from patients with T2DM but not from metabolically healthy subjects
caused insulin resistance in IgG-deficient mice via FcγRIIB, indicating that similar processes may be operative in T2DM in
humans. Mechanistically, the activation of FcγRIIB by IgG from obese mice impaired endothelial cell insulin transcytosis in
culture and in vivo. These effects were attributed to hyposialylation of the Fc glycan, and IgG from T2DM patients was also
hyposialylated. In HFD-fed mice, supplementation with the sialic acid precursor N-acetyl-D-mannosamine restored IgG
sialylation and preserved insulin sensitivity without affecting weight gain. Thus, IgG sialylation and endothelial FcγRIIB may
represent promising therapeutic targets to sever the link between obesity and T2DM.

Introduction

Diabetes is a major cause of morbidity and mortality and high
health care costs worldwide (1, 2). There has been an alarming rise
in the incidence of diabetes, with the number of adult diabetics
globally rocketing from 108 million in 1980 to 422 million in 2014
(3), and the bulk of the increase involves obesity-induced insulin
resistance and type 2 diabetes mellitus (T2DM) (4). Despite the
recognition that weight control measures are critically important
to T2DM prevention and management, long-term results from
lifestyle-directed or pharmacologic interventions are generally
disappointing (5, 6). Although our understanding of the mechanisms by which obesity causes insulin resistance and T2DM has
been improving (7), novel insights and therapeutic approaches are
urgently needed to combat the T2DM that so commonly complicates obesity.
A major aspect of obesity-induced insulin resistance is
impaired insulin action in the skeletal muscle, where up to 80%
of whole-body glucose disposal normally occurs (8, 9). In mice,
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diet-induced obesity causes a marked blunting of skeletal muscle
glucose disposal that occurs primarily because of a diminution
in skeletal muscle insulin delivery (10). Insulin delivery and participation in skeletal muscle glucose metabolism are intricately
influenced by processes occurring in the muscle microvasculature
(10). Via its actions in the endothelium, insulin promotes capillary recruitment and increases blood flow in skeletal muscle, and
the ultimate delivery of insulin from the circulation to the myocyte requires endothelial transcytosis of the hormone (11). These
collective processes promote skeletal muscle glucose disposal.
Potential clues regarding pathologic processes in skeletal muscle endothelium that may underlie insulin resistance arose from
our recent studies of the pentraxin C-reactive protein (CRP).
The studies were prompted by clinical reports of an association
between T2DM and modest elevations in CRP, which occur in
the setting of obesity and other chronic inflammatory conditions
(12–14). Using a CRP transgenic mouse, we showed that an elevation in CRP causes insulin resistance and that this is mediated by
FcγRIIB (15), which is an inhibitory receptor for IgG that also governs cellular responses to CRP and the related mouse pentraxin
serum amyloid P (SAP) component (16–18). We further revealed
that FcγRIIB is expressed in both human and mouse endothelium,
particularly in skeletal muscle microvascular endothelium; that an
elevation in CRP attenuates insulin delivery to skeletal muscle in
jci.org   Volume 128   Number 1   January 2018
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Figure 1. FcγRIIB–/– mice are protected
from obesity-induced glucose intolerance
and insulin resistance. Beginning at 5
weeks of age, male FcγRIIB+/+ and FcγRIIB–/– mice were fed a control diet (Con)
or a HFD for 12 weeks, and BW (A) and fat
and lean mass (B and C) were evaluated.
Fasting blood glucose (D) and insulin (E)
levels were measured (n = 7–13), and a GTT
(F) was performed. Following a 1-week
recovery while continuing the assigned
diets, the mice were fasted, and an ITT
(G) was performed. (F and G) n = 6–13. *P
< 0.05 versus FcγRIIB+/+ control; †P < 0.05
versus FcγRIIB+/+ HFD. (H) Following another week of recovery, the mice were fasted,
and [3H]-2-deoxyglucose (3H-2-DOG)
uptake in skeletal muscle was measured.
n = 7–8. (I–K) Euglycemic-insulinemic
clamps were performed on mice on a HFD,
and the GIR (I), peripheral Gd (J), and skeletal glucose uptake (K) were evaluated.
n = 5–6. Values represent the mean ±
SEM. *P < 0.05, **P < 0.01, ***P < 0.005,
and ****P < 0.001, by 1-way ANOVA with
Tukey’s post-hoc test (A–E and H), 2-way
ANOVA with Tukey’s post-hoc test (F and
G), and Student’s t test (I–K).

vivo and the transendothelial transport of insulin in cell culture;
and that the activation of FcγRIIB in endothelium in response to
an increase in CRP disrupts skeletal muscle glucose disposal and
thereby invokes insulin resistance (15, 18, 19). The perturbations
in glucose homeostasis observed in mice when CRP is artificially
elevated to increase the abundance of an FcγRIIB ligand phenocopy many of the features of obesity-induced insulin resistance
(10). However, whether FcγRIIB or any of its ligands participate in
obesity-induced insulin resistance is unknown.
Prompted by the need to better understand the pathogenesis of
obesity-related glucose dysregulation, we sought to determine the
potential role of Fc receptors in obesity-induced insulin resistance. We
designed experiments in mice and in cell culture to test the hypothesis that FcγRIIB mediates obesity-induced insulin resistance. We also
performed studies to address the following additional questions: (a)
If FcγRIIB is required, in what cell type does the receptor participate
in obesity-induced insulin resistance? (b) What is the ligand for FcγRIIB in its mediation of obesity-induced insulin resistance? (c) How is
the ligand altered during obesity? (d) Is there any evidence that processes revealed in obese mice may translate to humans with T2DM?
(e) Can the diabetogenic FcγRIIB ligand be manipulated during the
development of obesity to prevent insulin resistance?
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Results

Role of FcγRIIB. To first determine whether FcγRIIB participates in obesity-induced insulin resistance, WT (FcγRIIB+/+)
and FcγRIIB –/– mice were fed a control chow diet or a high-fat
diet (HFD) for 12 weeks, and body composition and glucose
homeostasis were evaluated. The 2 genotype groups displayed
comparable increases in BW and fat mass and correspondingly
similar declines in lean body mass on the HFD (Figure 1, A–C).
In addition, we observed no differences between FcγRIIB+/+
and FcγRIIB –/– mice in the alterations of food consumption or
energy expenditure that occurred with HFD-induced obesity
(Supplemental Figure 1, A–E; supplemental material available
online with this article; https://doi.org/10.1172/JCI89333DS1).
Circulating levels of triglycerides and free fatty acids were also
similar in HFD-fed FcγRIIB+/+ and FcγRIIB –/– mice (Supplemental Figure 2, A and B). Whereas FcγRIIB+/+ mice had elevated
fasting plasma glucose and insulin levels following HFD consumption, FcγRIIB –/– mice were protected from fasting hyperglycemia and had less fasting hyperinsulinemia than did FcγRIIB+/+
mice (Figure 1, D and E). In the FcγRIIB+/+ mice fed a HFD, glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs)
were predictably abnormal compared with those for chow-fed
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Figure 2. Mice with endothelium-specific deletion of FcγRIIB (FcγRIIBΔEC) are protected from obesity-induced glucose intolerance and insulin resistance
due to the preservation of skeletal muscle insulin delivery, insulin action, and glucose uptake. (A–C) Male FcγRIIBfl/fl and FcγRIIBΔEC mice were fed a
control diet or a HFD for 12 weeks, and BW (A) and fat and lean mass (B and C) were evaluated. n = 5–13 (A–C). Fasting blood glucose (D) and insulin (E)
levels were measured (n = 8–16), and a GTT (F; right panel shows the AUC) was performed. An ITT (G; right panel shows the AUC) and a PTT (H) were then
performed, each following a 1-week recovery while mice continued the assigned diets. (F–H) n = 6–13. (I) In separate mice, following 12 weeks on a HFD, a
hyperinsulinemic-euglycemic clamp was performed, and the GIR was calculated. n = 11–14. (J) One week after the PTT, the mice in A–H were fasted, and
[3H]-2-deoxyglucose uptake in skeletal muscle was measured. n = 7–8. (F–H) *P < 0.05 versus FcγRIIB+/+ control diet; †P < 0.05 versus FcγRIIB+/+ HFD. (K
and L) Following 12 weeks on a control diet or a HFD, mice were fasted and i.v. injected with PBS (Veh) or insulin (Ins) (1 unit/kg BW), and 5 minutes later,
skeletal muscle was harvested, the phosphorylation of Akt (Ser473) was assessed by immunoblotting (K), and muscle insulin content was measured by
ELISA (L). (K and L) n = 4–6. Values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.005, and ****P < 0.001, by 1-way ANOVA with Tukey’s posthoc test (A–E, and I–L), 2-way ANOVA with Tukey’s post-hoc test (F–H), and Student’s t test (I).

WT mice (Figure 1, F and G). In contrast, FcγRIIB –/– mice were
protected from HFD-induced glucose intolerance and insulin
resistance. Since classical functions of FcγRIIB often entail partnership with one of the activating Fc receptors — FcγRI, FcγRIII,
or FcγRIV (20) — we also sought to determine how activating
Fc receptor disruption by deletion of the shared γ chain impacts
obesity-induced insulin resistance. Fcγ+/+ and Fcγ–/– mice on a
HFD developed comparable obesity and comparable glucose
intolerance and insulin resistance (Supplemental Figure 3,
A–G), indicating that activating Fc receptors do not participate
in obesity-related glucose dysregulation.

We then determined the basis for the protection from obesity-
induced insulin resistance with FcγRIIB deletion. Noting that
FcγRIIB activation by an artificial elevation in CRP blunts muscle
glucose disposal (15), we next evaluated skeletal muscle glucose
uptake in FcγRIIB+/+ and FcγRIIB–/– mice on the 2 diets. Consumption of the HFD and the resulting obesity led to predictably
attenuated glucose uptake in the skeletal muscle of FcγRIIB+/+
mice. However, despite comparable obesity development, we
found that muscle glucose disposal was fully preserved in the
FcγRIIB–/– mice (Figure 1H). Euglycemic-hyperinsulinemic clamp
experiments further showed that, compared with FcγRIIB+/+ mice,
jci.org   Volume 128   Number 1   January 2018
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Figure 3. IgG isolated from HFD-fed WT mice induces
glucose intolerance and insulin resistance in B–/– mice via
endothelial FcγRIIB. (A) Male WT or B–/– mice were fed a
control diet or a HFD for 12 weeks, and a GTT was performed.
n = 7–9. *P < 0.05 versus WT control. (B and C) Male B–/– mice
were fed a HFD for 12 weeks, and while continuing the HFD,
they were i.p. injected with IgG (150 μg/mouse, 2 times/
week) isolated from WT mice fed either a control diet (ConIgG) or a HFD (HFD-IgG). GTTs (B) and ITTs (C) were performed
after 1 week and 2 weeks of IgG administration, respectively.
(B and C) n = 6–7. *P < 0.05 versus Con-IgG. (D and E) Using
the study design and readouts described for B and C, IgG
transfer experiments were performed in male B–/– mice given
IgG isolated from FcγRIIB–/– mice fed either a control diet or
a HFD. Endpoints were the GTT (D) and ITT (E). (D and E) n =
6–7. *P < 0.05 versus IgG from FcγRIIB–/– control mice. (F and
G) IgG transfer studies were performed in male B–/– versus B–/–
FcγRIIB–/– mice administered IgG isolated from HFD-fed WT
mice. GTTs (F) and ITTs (G) were performed. (F and G) n = 7–8.
*P < 0.05 versus B–/– mice. (H and I) IgG transfer experiments
were performed in male B–/– FcγRIIBfl/fl and B–/– FcγRIIBΔEC
mice administered IgG isolated from HFD-fed WT mice. GTTs
(H) and ITTs (I) were performed. (H and I) n = 11–14. *P < 0.05
versus B–/– FcγRIIBfl/fl mice. Values represent the mean ± SEM.
P values were determined by 2-way ANOVA with Tukey’s
post-hoc test.

HFD-fed FcγRIIB–/– mice had an increased glucose infusion rate
(GIR) and a greater glucose disposal (Gd) rate (Figure 1, I and J).
In addition, we confirmed the increase in skeletal muscle glucose
uptake observed with FcγRIIB deletion, despite diet-induced obesity (Figure 1K). There were no differences between HFD-fed FcγRIIB+/+ and FcγRIIB–/– mice in terms of serum insulin changes in
response to glucose (Supplemental Figure 4), nor were changes
detected in basal hepatic glucose production or hepatic insulin
sensitivity (Supplemental Figure 5). Collectively, these findings
indicate that, independent of effects on adiposity and independent of activating Fc receptors, FcγRIIB plays an important role
in obesity-induced insulin resistance by mediating the obesity-
induced decline in skeletal muscle glucose disposal. This is a
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jci.org   Volume 128   Number 1   January 2018

surprising discovery when one considers that FcγRIIB classically tempers immune responses (20) and
that numerous pathogenetic processes in obesity are
proinflammatory in nature (21).
Role of endothelial FcγRIIB. We next studied the role
of endothelial FcγRIIB in obesity-induced glucose dysregulation. This was accomplished using mice generated by crossing floxed FcγRIIB mice (FcγRIIBfl/fl) (19)
with vascular endothelial cadherin promoter–driven
Cre (VECad-Cre) mice (22). The resulting FcγRIIBfl/fl
VECad-Cre mice lacking the receptor in endothelium are designated herein as FcγRIIBΔEC mice. Compared with control diet–fed mice, upon HFD feeding,
FcγRIIBfl/fl and FcγRIIBΔEC mice showed similar BW
gains and fat mass expansion (Figure 2, A–C). There
were also no genotype-related differences in plasma levels of triglycerides or free fatty acids (Supplemental Figure 6, A and B). However, despite
equal degrees of adiposity, relative to FcγRIIBfl/fl
controls, FcγRIIBΔEC mice showed protection against
HFD-induced fasting hyperglycemia and hyperinsulinemia (Figure 2, D and E). FcγRIIBΔEC mice were also partially protected from
abnormal HFD-induced GTTs and ITTs (Figure 2, F and G), with
AUC calculations indicating 40%–54% protection. A 58% increase
in the GIR during euglycemic hyperinsulinemic clamps (Figure 2I)
provided additional evidence of an improvement in overall insulin
sensitivity, despite diet-induced obesity with selective endothelial FcγRIIB silencing. Pyruvate tolerance tests (PTTs) performed
to evaluate hepatic insulin sensitivity revealed that endothelial
cell FcγRIIB deletion affords no protection from obesity-induced
hepatic insulin resistance (Figure 2H). The improvement in overall
insulin sensitivity in HFD-fed FcγRIIBΔEC mice was instead related
to a normalization of skeletal muscle glucose uptake (Figure 2J).
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Figure 4. IgG isolated from human T2DM patients induces glucose intolerance and insulin resistance in B–/– mice via FcγRIIB. (A–D) Male B–/– mice
were fed a HFD for 12 weeks, and while continuing the HFD, they were i.p.
injected with IgG (150 μg/mouse, 2 times/week) isolated from non-T2DM
control subjects versus IgG from T2DM subjects. After 1 week of injections,
(A) BW was measured, (B) plasma glucose was measured after a 4- to
6-hour fast, and (C) a GTT was performed. (D) An ITT was performed following a second week of IgG injections. (A–D) n = 6 IgG samples, each evaluated in 3 to 5 mice. (C and D) *P < 0.05 versus Con-IgG. (E–G) Using the
study design described for A–D, IgG transfer experiments were performed
by administering human T2DM-IgG to male B–/– mice and B–/– FcγRIIB–/–
mice. (E) Fasting plasma glucose levels were measured before IgG injection
and at 1 week. n = 3 IgG samples. (F) A GTT was performed after 1 week of
injections, and (G) an ITT was performed after 2 weeks of injections. (F and
G) n = 3 IgG samples. *P < 0.05 versus B–/–. Values represent the mean ±
SEM. *P < 0.05, ***P < 0.005, ****P < 0.001, by Student’s t test (A and B,
with significance found in B), 1-way ANOVA with Tukey’s post-hoc test (E),
and 2-way ANOVA with Tukey’s post-hoc test (C, D, F, and G).

Next, to determine how endothelial FcγRIIB influences insulin
action in the skeletal muscle, we evaluated Akt phosphorylation in
muscle harvested 5 minutes after i.v. insulin injection (19) (Figure
2K). Insulin predictably caused a marked increase in Akt (Ser473)
phosphorylation in muscle in FcγRIIBfl/fl mice fed the control diet,
and the response was attenuated in FcγRIIBfl/fl mice following HFD
feeding. In contrast, in FcγRIIBΔEC mice, we observed a preservation of insulin activation of skeletal muscle Akt, despite HFD intake
and obesity. We then sought to determine how endothelial FcγRIIB
impacts skeletal muscle responses to circulating insulin in the setting
of obesity. Whereas a 257% increase in skeletal muscle insulin content was observed 5 minutes after insulin injection in the FcγRIIBfl/fl
mice fed a control chow diet, there was only a 32% increase in muscle insulin content in FcγRIIBfl/fl mice with diet-induced obesity (Figure 2L). In contrast, lean and obese FcγRIIBΔEC mice showed comparable 188% and 231% increases in insulin uptake in the skeletal
muscle following insulin administration. These cumulative findings
demonstrate that endothelial FcγRIIB is responsible for the decrease
in skeletal muscle insulin delivery that occurs in obesity and results
in impaired muscle glucose disposal and insulin resistance.
Identifying IgG as the operative FcγRIIB ligand. Having determined that there is an important role for FcγRIIB in obesity-
induced insulin resistance, we next sought to identify the opera-

tive receptor ligand. The 3 known ligands, IgG, CRP, and SAP, bind
to identical amino acids in the extracellular domain of Fc receptors
(17). Consistent with previous reports (23, 24), we found that neither plasma CRP nor SAP was elevated by diet-induced obesity in
mice (Supplemental Figure 7, A and B). However, since SAP is the
acute-phase reactant pentraxin in mice and CRP is not (25, 26),
and, as such, SAP abundance may change earlier during the genesis of obesity, we compared the development of obesity-induced
insulin resistance in SAP+/+ with that of SAP–/– mice. After 12 weeks
of HFD feeding, mice in both genotype groups had similar weight
gains and adiposity (Supplemental Figure 7, C–E), developed comparable fasting hyperglycemia and hyperinsulinemia (Supplemental Figure 7, F and G), and had similarly affected GTTs and ITTs
(Supplemental Figure 7, H and I). Thus, the murine acute-phase
reactant SAP did not participate in the pathogenesis of obesity-
induced insulin resistance in the mouse model.
With CRP and SAP unlikely to be the operative FcγRIIB ligand
in obesity-induced insulin resistance in mice, we investigated the
role of IgG in studies of Ig μ heavy-chain–null mice deficient in
mature B cells and IgG production (designated herein as B–/– mice).
As with previously reported findings (27), in contrast to WT controls, B–/– mice administered a HFD for 12 weeks did not develop
glucose intolerance (Figure 3A). In IgG transfer experiments involving HFD-fed B–/– recipients, IgG from WT mice fed a HFD (HFDIgG) induced glucose intolerance and insulin resistance, whereas
IgG from WT mice fed a control diet (Con-IgG) did not (Figure
3, B and C). Of note, HFD-IgG transfer to a lean B–/– mouse does
not cause insulin resistance (27), indicating that obesity-related
changes in IgG are necessary but not sufficient for the development
of insulin resistance. Circulating levels of total IgG (Supplemental
Figure 8A) and of the 4 individual mouse IgG subclasses IgG1,
IgG2b, IgG2c, and IgG3 (Supplemental Figure 8, B–E) were similar
in the control diet– versus HFD-fed mice. As such, changes in the
actions of IgGs, and not in their abundance, probably underlie their
participation in obesity-related insulin resistance.
Since FcγRIIB is expressed in B cells and modulates IgG production (20), the protection from obesity-induced insulin resistance seen in mice globally deficient in FcγRIIB (Figure 1) may
involve effects of receptor loss on IgG generation. This possibility was tested in IgG transfer experiments using IgG from control
jci.org   Volume 128   Number 1   January 2018
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Figure 5. IgG from HFD-fed mice attenuates insulin-induced eNOS activation and transendothelial transport of insulin via FcγRIIB and eNOS antagonism, and IgG from T2DM subjects blunts insulin action in human endothelium via FcγRIIB. (A) BAECs were preincubated for 30 minutes with IgG isolated from control diet–fed (Con-IgG) or HFD-fed (HFD-IgG, 10 μg/ml) mice, and eNOS activity stimulated by insulin (100 nM) was measured. n = 6. (B and
C) BAECs were transfected with or without control RNAi or RNAi targeting FcγRIIB. Downregulation of FcγRIIB was assessed by immunoblotting (B) using
anti-FcγRIIB or anti-eNOS antibody to evaluate protein loading. (C) Forty-eight hours after transfection, cells were pretreated with CRP (25 μg/ml), ConIgG, or HFD-IgG (10 μg/ml) for thirty minutes, and eNOS activity stimulated by insulin was measured. n = 16. (D) HAECs were preincubated with Con-IgG
or HFD-IgG (10 μg/ml), and eNOS activity under basal conditions or with insulin treatment was measured. n = 3. (E) Confluent HAEC monolayers on Transwells were preincubated for 30 minutes with CRP, Con-IgG, or HFD-IgG in the absence or presence of the NOS inhibitor L-NAME (2 mM) or the NO donor
SNAP (100 nM). FITC-conjugated insulin (50 nM) was added to the upper chamber, and the amount of insulin transcytosed to the lower chamber was
evaluated after 2 hours. n = 7. (F) Using the study design and methods described for E, endothelial cell insulin transcytosis was evaluated without versus
with CRP, Con-IgG, or HFD-IgG treatment, in the presence of subtype-matched control antibody (C, 10 μg/ml) or the FcγRIIB-blocking antibody AT10 (BL, 10
μg/ml). n = 6. (G) Insulin-induced eNOS activation was evaluated in HAECs with or without treatment with IgG from nondiabetic individuals (Con) or T2DM
patients. n = 6. (H) Additional NOS activity assays were performed in the presence of the subtype-matched control antibody (C) or the FcγRIIB-blocking
antibody (BL). n = 3. Values represent the mean ± SEM. *P < 0.05, ***P < 0.005, and ****P < 0.001, by 1-way ANOVA with Tukey’s post-hoc test.

chow-fed versus HFD-fed FcγRIIB–/– mice. Mimicking the findings
obtained with IgG from WT mice, in contrast to IgG from control chow-fed FcγRIIB–/– mice, IgG from HFD-fed FcγRIIB–/– mice
caused glucose intolerance and insulin resistance (Figure 3, D and
E). Thus, the role of FcγRIIB in obesity-related insulin resistance
does not involve its function in B cells; instead, it resides in a target cell of IgG action. This was further explored in an IgG transfer
experiment comparing responses to IgG obtained from WT mice
fed a HFD (HFD-IgG) administered to HFD-fed B–/– mice versus
responses by HFD-fed B–/– FcγRIIB–/– double-KO mice. Whereas HFD-IgG caused abnormal GTTs and ITTs when given to B–/–
mice, we observed normal glucose tolerance and insulin sensitivity
after HFD-IgG transfer into B–/– FcγRIIB–/– mice (Figure 3, F and
G). We further assessed the FcγRIIB-expressing IgG target cell
of relevance using HFD-fed B–/– FcγRIIBfl/fl mice versus HFD-fed
B–/– FcγRIIBΔEC mice as IgG recipients. Whereas HFD-IgG caused
abnormal GTTs and ITTs when given to B–/– FcγRIIBfl/fl mice, the
B–/– FcγRIIBΔEC recipients of HFD-IgG had normal glucose tolerance and insulin sensitivity (Figure 3, H and I). Paralleling the
314
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protection from obesity-induced insulin resistance observed in
FcγRIIBΔEC mice (Figure 2), these findings indicate that IgG is the
operative FcγRIIB ligand in the disorder and that the relevant IgG
target cell in which FcγRIIB participates is the endothelial cell.
IgG and T2DM in humans. We next examined whether the
IgG-FcγRIIB tandem plays a potential role in T2DM in humans.
We performed IgG transfer studies in HFD-fed B–/– mice given
IgG isolated from insulin-sensitive/nondiabetic control human
subjects (n = 6) versus IgG from human subjects with T2DM
(T2DM-IgG) (n = 6) (Supplemental Table 1). Following receipt
of the control versus T2DM human IgG, we found no difference
in BW (Figure 4A). However, compared with mice given control
IgG, mice that received T2DM-IgG developed relative fasting
hyperglycemia and had abnormal GTTs and ITTs (Figure 4, B–D).
A requirement for FcγRIIB in T2DM-IgG–induced glucose intolerance and insulin resistance was then tested using HFD-fed B–/–
mice and B–/– FcγRIIB–/– mice as recipients. Prior to receiving IgG,
the mice in the 2 genotype groups had comparable fasting glucose
levels (Figure 4E). However, after injections of T2DM-IgG, the B–/–

The Journal of Clinical Investigation  
mice had hyperglycemia and abnormal GTTs and ITTs, whereas
the B–/– FcγIIB–/–mice did not (Figure 4, E–G). Thus, in contrast
to IgG obtained from healthy human subjects, IgG isolated from
T2DM subjects caused glucose intolerance and insulin resistance
in mice, and FcγRIIB was required for the effect.
IgG and FcγRIIB actions in endothelium. Next, to identify the
actions of IgG that adversely affect glucose homeostatic mechanisms via FcγRIIB in endothelium, we took advantage of the
knowledge that in cultured endothelial cells, FcγRIIB stimulation
antagonizes insulin activation of endothelial NOS (eNOS) (28).
We compared eNOS activation by insulin in cultured bovine aortic endothelial cells (BAECs) exposed to IgG isolated from control
mice (Con-IgG) versus IgG isolated from mice who had received
a HFD (HFD-IgG). Whereas Con-IgG had no effect, HFD-IgG
inhibited insulin-induced eNOS activation (Figure 5A). To then
determine whether FcγRIIB is required, BAECs were transfected
with control RNAi or RNAi targeting FcγRIIB to downregulate
receptor expression (Figure 5B), and IgG actions were compared
with those of CRP, a positive control FcγRIIB ligand known to
inhibit eNOS (28). In cells with a normal complement of endogenous FcγRIIB, CRP inhibited insulin-stimulated eNOS activation
as expected, and HFD-IgG had a similar effect (Figure 5C). In
contrast, neither CRP nor HFD-IgG blunted insulin activation of
eNOS in endothelial cells deficient in FcγRIIB.
Next, we determined whether HFD-IgG modulation of insulin
action occurs in human endothelium in studies of primary human
aortic endothelial cells (HAECs). Mirroring the findings in BAECs,
whereas Con-IgG did not alter insulin activation of eNOS in
HAECs, HFD-IgG attenuated the response to insulin (Figure 5D).
Knowing that insulin signaling and NO regulate the transcytosis
of insulin by endothelial cells that is requisite for insulin action
in skeletal muscle (29), we then evaluated the possible effects of
HFD-IgG on endothelial cell insulin transcytosis in HAECs (Figure
5E). CRP as a positive control (19) caused a decline in insulin transcytosis, Con-IgG had no effect, and HFD-IgG caused a reduction
in transcytosis comparable to that observed with CRP. NOS antagonism with nitro-L-arginine methyl ester (L-NAME) had an effect
similar to that of HFD-IgG, and the latter was reversed by the NO
donor S-nitroso-N-acetyl-penicillamine (SNAP) (Figure 5E) and
also by a blocking antibody against human FcγRIIB (AT10) (Figure
5F). Evaluations of paracellular transport using FITC-dextran and
measurements of transendothelial electrical resistance (TEER)
(Supplemental Figure 9, A–D) indicated that monolayer integrity
remained intact under all the conditions studied. Importantly,
the marked FcγRIIB-dependent diminution in endothelial insulin
transcytosis observed with HFD-IgG treatment in culture parallels our discovery that the obesity-related loss of skeletal muscle
insulin delivery in vivo is fully reversed by endothelial FcγRIIB
silencing (Figure 2L). Since muscle insulin delivery in vivo is influenced by both insulin-induced changes in muscle capillary recruitment and blood flow and processes governing insulin transcytosis across the endothelial monolayer (30), we examined how the
receptor may impact muscle microvascular functional responses
to insulin in the setting of diet-induced obesity in vivo. We accomplished this using dynamic contrast-enhanced ultrasound (DCEUS) imaging of the proximal hind limb adductor muscle group and
signal time-intensity curve analysis to assess capillary blood vol-
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ume (CBV) and microvascular blood flow (MBF) at baseline and at
the end of a 2-hour hyperinsulinemic-euglycemic clamp in HFDfed FcγRIIB+/+ and FcγRIIB–/– mice. The GIR during the clamps was
greater in FcγRIIB–/– mice (Supplemental Figure 10A), mirroring
the findings in Figure 1I. In DCE-US, peak intensity (Ipk) reflects
CBV, the time to peak (Tpk) and wash-in rate (WIR) reflect MBF,
and the AUC and wash-out rate (WOR) are affected by both CBV
and MBF. The Ipk was similar in the 2 genotype groups at baseline,
and there were similar increases in responses to insulin (Supplemental Figure 10B). Tpk and WIR reflecting MBF were similar
at baseline in FcγRIIB+/+ and FcγRIIB–/– mice, and they did not
change in response to insulin (Supplemental Figure 10, C and D).
The AUC and WOR, which are affected by both CBV and MBF,
were comparable in the 2 genotype groups at t0, and they rose
equivalently with insulin infusion (Supplemental Figure 10, E and
F). As such, insulin induced an increase in CBV but did not affect
MBF in obese FcγRIIB+/+ or FcγRIIB–/– mice, and the responses
were similar in the 2 genotype groups. Our observations of skeletal
muscle insulin delivery in vivo (Figure 2L) and insulin transcytosis
in cultured endothelial cells (Figure 5, E and F) indicate that the
impairment in skeletal muscle insulin delivery that underlies obesity-related peripheral insulin resistance is primarily due to a diminution in endothelial insulin transcytosis caused by the IgG-endothelial FcγRIIB tandem.
Seeking evidence of a possible adverse effect of human
T2DM IgG on insulin action in human endothelium of relevance to glucose homeostasis, we next evaluated insulin-
induced eNOS activation in HAECs in the presence of IgG from
insulin-sensitive individuals or subjects with T2DM. Similar to
mouse HFD-IgG (Figure 5D), T2DM-IgG inhibited eNOS activation by insulin (Figure 5G), and the inhibition was prevented
by the FcγRIIB-blocking antibody (Figure 5H). Thus, we found
parallel FcγRIIB-dependent negative effects of HFD-IgG from
mice and IgG from humans with T2DM on insulin action in
endothelium. These findings, in combination with the comparable detrimental in vivo effects of HFD-IgG from mice and IgG
from type 2 diabetics on insulin sensitivity in mice (Figures 3
and 4), suggest that the diabetogenic actions of the IgG–endothelial FcγRIIB tandem now revealed in obese mice may be
operative in T2DM in humans.
IgG hyposialylation and insulin resistance. To determine how
IgG is modified in obesity to adversely impact glucose homeostasis via FcγRIIB in endothelium, we isolated subclasses of IgG
from control-fed and HFD-fed mice and tested their effects on
insulin activation of eNOS in cultured endothelial cells. Studies
were performed with IgG1, IgG2b, and IgG2c, because they bind
to FcγRIIB and IgG3 does not (31). Using CRP as a positive control, we found that IgG1 and IgG2b from HFD-fed mice did not
affect insulin activation of eNOS (Figure 6, A and B). In contrast,
whereas IgG2c from control-fed mice had no effect, IgG2c from
HFD-fed mice fully antagonized insulin stimulation of eNOS
(Figure 6C). Recognizing that the relative glycosylation, particularly the sialylation of the Fc glycan on IgG, affects IgG affinity
for Fc receptors (32), we then compared the sialylation of IgG2c
isolated from control diet– versus HFD-fed mice by Sambucus
nigra agglutinin (SNA) lectin blotting (33). The presence of sialic
acid on the Fc glycan reduces FcγRIIB affinity by 10-fold (32).
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Figure 6. Hyposialylated IgG2c from HFD-fed mice blunts endothelial insulin transcytosis and invokes insulin resistance via FcγRIIB, and IgG from T2DM
subjects is similarly hyposialylated. (A–C) The effects of the IgG subclasses IgG1 (A), IgG2b (B), or IgG2c (C) (10 μg/ml) from control diet– or HFD-fed WT
mice on eNOS activation by insulin (100 nM) were assessed in cultured endothelial cells. (A–C) n = 6–11. (D) Sialylation of IgG2c (Sial-IgG2c) from control diet–
or HFD-fed mice was evaluated by SNA-lectin blotting. n = 6. (E) Sialylation of IgG isolated from nondiabetic humans and T2DM patients was evaluated by
SNA-lectin blotting. n = 6. (F) IgG2c from control diet– or HFD-fed mice was treated with vehicle (Con) or NA, and sialylation was evaluated by SNA-lectin
blotting. n = 3. (G) Endothelial cells were preincubated with Con-IgG2c or HFD-IgG2c treated with vehicle or NA, and eNOS activation by insulin was assessed.
n = 6. (H) Confluent endothelial cells on Transwells were preincubated with Con-IgG2c or HFD-IgG2c treated with vehicle or NA, and insulin transcytosis was
assessed in the absence or presence of the NO donor SNAP (100 nM), control antibody (C, 10 μg/ml), or FcγRIIB-blocking antibody (BL, 10 μg/ml). n = 7. (I–K)
B–/– mice were fed a HFD for 12 weeks and injected with Con-IgG that was treated ex vivo with vehicle (Con-IgG) or NA (NA-IgG). Fasting plasma glucose was
measured before and after 1 week of injections (I), and then GTTs (J) and ITTs (K) were performed. (I–K) n = 7–16. *P < 0.05, NA versus Con-IgG. (L and M)
Using the same study design as in I–K, IgG transfer experiments were performed in B–/– and B–/– FcγRIIB–/– mice administered Con-IgG or NA-IgG. GTTs (L) and
ITTs (M) were performed. (L and M) n = 5–6. *P < 0.05, B–/– NA-IgG versus B–/– Con-IgG; †P < 0.05, B–/– FcγRIIB–/– versus B–/–. (N) The Fc Asn297–associated glycan structure was evaluated by glycoproteomic analysis using pooled mouse Con-IgG2c and HFD-IgG2c. Values represent the mean ± SEM (A–M). *P < 0.05,
**P < 0.01, ***P < 0.005, and ****P < 0.001, by 1-way ANOVA with Tukey’s post-hoc test (A–C and F–I), Student’s t test (D and E), and 2-way ANOVA (J–M).
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Figure 7. ManNAc treatment protects mice from obesity-induced
glucose intolerance and insulin resistance. (A) Male WT mice were
fed a HFD and either regular drinking water (control) or ManNAc-supplemented drinking water for 6 weeks. Plasma IgG was isolated, and
its sialylation was evaluated by SNA-lectin blotting. Graph depicts the
relative sialylation. n = 5. (B) BW and (C) fasting plasma glucose levels
were measured, and (D) a GTT was performed. (E) Mice were continued
on the HFD, and an ITT was performed 1 week later. n = 9. (A–E) Values
represent the mean ± SEM. (A–C) *P < 0.05 and ****P < 0.001, by
Student’s t test; (D and E) *P < 0.05, ManNAc versus control, by 2-way
ANOVA with Tukey’s post-hoc test.

We found that HFD-IgG2c was less sialylated than Con-IgG2c
(Figure 6D) and, in contrast, that there was no difference in the
sialylation of IgG1 or IgG2b isolated from control diet– or HFDfed mice (Supplemental Figure 11). We then evaluated the time
course of temporal changes in IgG2c sialylation versus evidence
of glucose intolerance during the development of diet-induced
obesity in mice (Supplemental Figure 12). After 2 weeks on a
HFD, IgG2c sialylation was unaltered, and the mice had not yet
developed glucose intolerance. However, paralleling a decline
in IgG2c sialylation after 4 weeks on a HFD, glucose intolerance
was evident, and these abnormalities persisted thereafter. Thus,
there is a temporal relationship between the development of
IgG2c hyposialylation and the development of abnormal glucose
homeostasis over the course of HFD-induced obesity in mice.
Prompted by the findings regarding IgG2c sialylation in mice,
we compared the sialylation levels of IgG isolated from insulin-sensitive human subjects with sialylation levels of IgG from
individuals with T2DM (Figure 6E) and discovered a decrease in
sialylation of IgG in the T2DM subjects.
Next, we determined whether the degree of sialylation of IgG
influences its capacity to alter insulin action in endothelial cells.
IgG2c from control diet– and HFD-fed mice was treated with
neuraminidase (NA) to invoke desialylation (Figure 6F), and the
resulting effects on insulin activation of eNOS in cultured endothelial cells were evaluated. We found that NA-treated, hyposialylated control IgG2c antagonized insulin activation of eNOS to
a degree similar to that found with nontreated HFD-IgG2c (Figure
6G). Direct endothelial cell treatment with NA had no impact on
insulin activation of eNOS (Supplemental Figure 13A). We also
evaluated the effects of IgG hyposialylation on endothelial cell
insulin transcytosis (Figure 6H). Transcytosis was comparably
inhibited by HFD-IgG and NA-treated Con-IgG, and the inhibition by NA-treated Con-IgG was fully reversed by the NO donor
SNAP or by the anti-FcγRIIB–blocking antibody.

We then tested whether the hyposialylation of IgG invokes
insulin resistance in vivo by performing IgG transfer experiments
in HFD-fed B–/– mice. The administration of control-treated or
NA-treated IgG had no effect on BW (Supplemental Figure 13B).
However, whereas mice given control-treated IgG had no change
in fasting glucose compared with baseline values, mice given
NA-treated IgG developed fasting hyperglycemia (Figure 6I).
In parallel, GTTs were shifted upward in mice given NA-treated
IgG but not in mice given control-treated IgG, and ITTs were also
abnormal in the former group compared with ITTs in the latter
(Figure 6, J and K). The administration of NA alone to mice had
no effect on GTT or ITT values (Supplemental Figure 13, C and
D). Furthermore, whereas NA-treated IgG induced glucose intolerance and insulin resistance in B–/– mice, it had no effect in B–/–
FcγRIIB–/– mice (Figure 6, L and M).
Having implicated IgG2c hyposialylation in obesity-induced
insulin resistance in mice, we used mass spectrometry (MS) to
provide specific structural analysis of the glycan attached to Fc
Asn297 in IgG2c from control diet–fed and HFD-fed mice (Figure
6N and Supplemental Table 2). We found that, whereas 19.2% of Fc
Asn297–associated glycans in Con-IgG2c were terminally sialylated, HFD-IgG2c Fc Asn297 glycans had no detectable sialylation.
However, the abundance of the sugar moieties proximal to the terminal sialic acid was similar in Con-IgG2c and HFD-IgG2c. These
collective results reveal that IgG2c is hyposialylated in the setting
of diet-induced obesity in mice; that in parallel IgG sialylation is
decreased in humans with T2DM; that the hyposialylation causes
IgG to antagonize endothelial cell insulin transcytosis via FcγRIIB
and eNOS antagonism; and that the IgG hyposialylation invokes
glucose intolerance and insulin resistance in vivo in mice through
processes mediated by FcγRIIB.
Rescue of IgG sialylation and prevention of insulin resistance.
Having implicated the hyposialylation of IgG in obesity-induced
insulin resistance, we next investigated how the promotion of
sialylation potentially impacts the disorder. WT mice placed on a
HFD at 5 weeks of age were concurrently given either water alone
or water supplemented with the sialic acid precursor N-acetylmannosamine (ManNAc) (34). Six weeks later, we observed an
increase in sialylation in IgG isolated from the ManNAc-treated
mice (Figure 7A). In the absence of any impact on BW (Figure 7B),
ManNAc treatment improved fasting glucose, and GTTs and ITTs
revealed that ManNAc afforded protection from obesity-induced
glucose intolerance and insulin resistance (Figure 7, C–E). Thus,
it may be possible to prevent obesity-related insulin resistance by
normalizing the sialylation of IgG.
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Discussion

T2DM is a common complication of obesity and an important
cause of morbidity and mortality worldwide, and its prevalence is
increasing. In studies of diet-induced obesity in mice, we reveal
that the inhibitory IgG receptor FcγRIIB in endothelial cells surprisingly plays an important role in obesity-induced insulin resistance. Despite developing an increase in adiposity on a HFD
comparable to that seen in control mice, mice globally deficient
in FcγRIIB as well as mice lacking the receptor selectively in endothelium were protected from insulin resistance. This was due to a
normalization in skeletal muscle glucose disposal resulting from a
preservation of skeletal muscle insulin delivery. We further determined that the operative ligand for endothelial FcγRIIB invoking
obesity-induced insulin resistance was IgG and also showed that
Fc receptor activation, and not the previously suggested autoantigen recognition by IgG during obesity, is critical to the pathogenesis of the disorder. Importantly, we have demonstrated for the first
time to our knowledge that, in contrast to IgG isolated from metabolically healthy human subjects, IgG from patients with T2DM
invokes insulin resistance when given to B cell–deficient mice,
and in human endothelial cells, it blocks insulin action. Moreover,
both the in vivo detrimental response to human T2DM IgG in
mice and its direct inhibitory effect on insulin function in human
endothelial cells required FcγRIIB, providing evidence that these
mechanisms may be operative in T2DM in humans. Thus, endothelial FcγRIIB activation by IgG has been identified as a critical
mechanism contributing to the pathogenesis of obesity-induced
insulin resistance.
Whereas FcγRIIB classically influences immune responses
in B cells, T cells, DCs, and monocytes/macrophages (35), it is
only recently that FcγRIIB expression and governance of cellular
responses has been recognized in endothelium. FcγRIIB protein
was found to be abundant in microvascular endothelium, particularly in skeletal muscle (15), and the receptor protein was also
readily detected by FACS in human endothelial cells from various
vascular beds (18). Recently, we discovered that the activation
of endothelial FcγRIIB by an artificial elevation of the pentraxin
CRP in mice causes insulin resistance (19). However, it was entirely unknown whether FcγRIIB, CRP, the murine CRP-equivalent
acute-phase reactant SAP, the classical receptor ligand IgG, or
any related mechanisms participate in obesity-induced insulin
resistance. A role for FcγRIIB in obesity-related disease was first
demonstrated when we determined that mice globally deficient
in the receptor are protected from obesity-induced hypertension
(24). Although further elucidation of the processes whereby the
receptor causes blood pressure elevation in obesity is required,
the available evidence to date suggests that the hypertension and
insulin resistance that complicate obesity may have shared mechanistic origins centered on FcγRIIB.
Turning to the relevant FcγRIIB ligand and its cellular source,
B cell involvement in obesity-induced insulin resistance was previously demonstrated in studies showing preservation of normal
insulin sensitivity in B–/– mice, despite the development of obesity
on a HFD (27, 36). The contribution of B cells to diabetes has been
attributed to their regulation of T cell function and macrophage
activation and to the effects of autoantibodies targeting self-
antigens including islet autoantigens and autoantigens in other
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cell types (21, 27, 36). Interestingly, in IgG transfer experiments,
Winer and colleagues (27) found that, whereas intact HFD-IgG
causes glucose intolerance, F(ab′)2 fragments have no effect,
consistent with our identification of an Fc receptor, specifically
FcγRIIB, as a critical participant in the pathogenesis of obesity-
induced insulin resistance. Further demonstrating the requirement for endothelial FcγRIIB in the adverse effects of HFD-IgG on
insulin sensitivity, our search for the basis for altered IgG action
excluded changes in IgG abundance. Alternatively, through IgG
glycosylation analysis including MS and its manipulation by sialic
acid removal with NA, we determined that the glucose intolerance
and insulin resistance invoked in mice by HFD-IgG was uniquely
related to its hyposialylation in the setting of obesity. We further
found that there was relative hyposialylation of IgG from T2DM
patients compared with that from healthy controls. The glycan
attached to asparagine 297 in the Fc region of IgG influences the
binding of IgG to Fc receptors, presumably by changing the conformation of Fc, with the absence of the terminal sialic acid residue
increasing receptor affinity (32). IgG glycosylation status has been
shown to be of potential importance in rheumatoid arthritis and in
the protective effect of i.v. IgG (IVIG) (33, 37). We now provide evidence that this form of immune response modulation may participate in an extremely common clinical condition, namely T2DM.
Interestingly, our evidence includes demonstrations in mice that
the hyposialylation of the relevant IgG subclass IgG2c and glucose
intolerance are first observed concomitantly after 4 weeks of HFD
feeding. As such, loss-of-function, gain-of-function, and temporal association studies have consistently implicated altered IgG
sialylation and FcγRIIB in obesity-induced insulin resistance.
In addition to revealing the involvement of endothelial FcγRIIB
and its activation by hyposialylated IgG in obesity-induced insulin
resistance, we elucidated their pathogenic mechanisms of action.
It was previously shown that diet-induced obesity causes a marked
attenuation in skeletal muscle insulin delivery (10). However, the
basis for the blunting of insulin delivery in obesity was unknown.
By cell-specific genetic loss of function, we discovered that endothelial FcγRIIB is required for the obesity-related impairment in
skeletal muscle insulin delivery. Insulin transcytosis studies in cultured endothelial cells further revealed that, as a result of its hyposialylation, HFD-IgG causes an FcγRIIB-dependent decline in
insulin transcytosis that is related to eNOS antagonism. DCE-US
experiments in mice further revealed a lack of impact of FcγRIIB
on muscle capillary recruitment or MBF responses to insulin in
the setting of obesity, indicating that FcγRIIB attenuation of endothelial insulin transcytosis most likely explains how the receptor
in endothelium impairs skeletal muscle insulin delivery in obese
mice. Whereas endothelial FcγRIIB deletion reversed obesity-related processes in the skeletal muscle, there was no effect on the
hepatic insulin resistance that also accompanies obesity. FcγRIIB
modulation of endothelial insulin transcytosis may be irrelevant
to hepatic glucose homeostasis, because, in contrast to the skeletal muscle microvasculature, discontinuous endothelium is found
in liver sinusoidal vascular beds, and liver sinusoidal endothelium
also possess large fenestrations (38).
Having revealed that the terminal hyposialylation of IgG
plays an important role in the insulin resistance associated with
obesity, the opportunity arose to test whether the promotion of
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sialylation prevents the insulin resistance. Supplementation of
the drinking water with the sialic acid precursor ManNAc effectively normalized IgG sialylation and glucose intolerance and
insulin resistance in mice fed a HFD for 6 weeks, without impacting weight gain. Treatment with ManNAc is currently under
consideration in individuals with the autosomal recessive neuromuscular disorder hereditary inclusion body myopathy (HIBM)
(39), which is caused by mutations in the GNE gene that encodes
ManNAc kinase, which catalyzes the first 2 rate-limiting steps
in sialic acid synthesis (34). Thus, entirely independent of other
interventions targeting the underlying obesity, it may be possible
to intervene against T2DM by sialic acid supplementation. Such
an approach, as well as strategies affording selective inhibition of
endothelial FcγRIIB, may offer unique opportunities to sever the
link between obesity and insulin resistance that now afflict millions of individuals worldwide.

Methods

Animal model. Experiments were performed in male C57BL/6 WT,
FcγRIIB –/–, Fcγ–/–, B –/–, SAP –/–, FcγRIIBfl/fl, and VECad-Cre mice,
or in offspring from their mating. FcγRIIB –/– mice were obtained
from T. Takai (Tohoku University, Sendai, Japan) (15); Fcγ–/– mice
were obtained from Taconic Biosciences; and B –/– mice were purchased from The Jackson Laboratory. SAP –/– mice were produced
as described previously (40). FcγRIIBfl/fl mice were generated and
backcrossed with C57BL/6 mice for more than 8 generations as
previously reported (19), and FcγRIIBΔEC mice were produced by
breeding FcγRIIBfl/fl mice with VECad-Cre mice (19). Beginning at 5
weeks of age, the study mice were fed either a control diet (Research
Diets; D12329, with 11% kcal from fat) or a HFD (Research Diets;
D12331, with 58% kcal from fat) (41, 42), and experiments were
performed 12–14 weeks later. In a select set of experiments, ManNAc (Sigma-Aldrich) was given in the drinking water (1%). Concentrations of plasma CRP, SAP, total IgG or IgG subclasses in mice
were measured using ELISA reagents from Life Diagnostics, Immunology Consultants Laboratory Inc., ZeptoMetrix Corporation, and
Bethyl Laboratories, respectively. Plasma triglycerides were measured by colorimetric enzymatic assay, and plasma free fatty acids
were quantified using the VITROS 250 Chemistry System as previously described (43).
Evaluation of body composition, food consumption, and energy
expenditure. BW was measured, and fat mass and lean body mass were
determined by NMR (Minispec NMR Analyzer; Bruker) (15). Food
consumption and energy expenditure were measured during control diet or HFD feeding over a 4-day period, after 10 weeks on the
assigned diets. Following acclimatization for 6 days, indirect calorimetry and activity were simultaneously measured in the Mouse Metabolic Phenotyping Core at the University of Texas Southwestern using
the Comprehensive Laboratory Animal Monitoring System (Columbus Instruments) (15).
Evaluation of glucose homeostasis and its regulation. GTTs, ITTs,
and PTTs were performed as described previously. Following a 4- to
6-hour fast, the mice received an i.p. injection of D-glucose (1 g/kg
BW), insulin (1 unit/kg BW), or pyruvate (2 g/kg BW), respectively
(15, 44). Tail vein blood samples were obtained at the indicated times
(Figures 1–4, 6, and 7) for plasma glucose measurement by glucometer (ONE TOUCH Ultra2; Johnson & Johnson). Fasting plasma insulin
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concentrations were determined by ELISA (Crystal Chem Inc.; 90080
Ver. 15) (15). Hyperinsulinemic-euglycemic clamps were performed as
previously described (15, 45). In brief, hyperinsulinemia was initiated
with a primed continuous infusion of insulin (10 mU/kg/min), while
variable infusion of 50% dextrose allowed for the achievement of a
targeted blood glucose level near 125 mg/dl. Constant infusion of
3
H-glucose for 90 minutes prior to the clamp and throughout the duration of the experiment allowed for calculations of glucose kinetics.
Evaluations of skeletal muscle glucose uptake, insulin signaling,
and insulin delivery were performed as previously reported (15, 19). To
assess skeletal muscle glucose uptake, fasted mice were injected i.p.
with 2-deoxy-[3H]glucose ([3H]-2-DOG; 2 g/kg; 10 μCi/mouse; Amersham Radiolabeled Chemicals) mixed with dextrose (20%), and blood
glucose was measured at 0 to 90 minutes. The plasma was deproteinized with ice-cold perchloric acid, the supernatant was neutralized
with KHCO3, and radioactivity was determined in a liquid scintillation
counter. The glucose-specific activity (degenerations/min/μmol) was
calculated by dividing the radioactivity by the glucose concentration,
and the AUC was integrated for the duration of the experiment (90
min). Skeletal muscle (soleus and gastrocnemius) was harvested at
90 minutes. To measure the accumulation of [3H]-2-DOG, muscles
were homogenized, the homogenate was precipitated with ice-cold
perchloric acid, and following centrifugation, the supernatant was
neutralized for 30 minutes with KHCO3, and 2 aliquots were prepared.
One aliquot was used to determine total 3H radioactivity, and the other
was passed through an anion exchange column (AG 1-X8 Resin; BioRad) to remove unbound [3H]-2-DOG-6-phosphate. The column was
washed with distilled water, and the radioactivity in the eluted volume
was measured in a scintillation counter. The difference between total
and eluted 3H radioactivity represents accumulated [3H]-2-DOG-6phosphate. The protein pellet was digested with KOH, and the protein
concentration was determined by Bradford assay (Bio-Rad). To calculate [3H]-2-DOG uptake, the radioactive counts (degenerations/min)
were divided by the integrated glucose-specific activity AUC and the
sample protein content.
To evaluate skeletal muscle insulin signaling to Akt and insulin
delivery, fasted mice received tail vein injections of vehicle (saline)
or bovine insulin (1 units/kg BW), the soleus and gastrocnemius were
harvested and homogenized in PBS 5 minutes later, and the homogenates were prepared for protein determination by Bradford assay and
insulin measurements by ELISA (Crystal Chem Inc.). Phosphorylated Akt (p-Akt) and total Akt were detected by immunoblotting using
polyclonal anti–p-Akt (S473; Cell Signaling Technology) and anti-Akt
antibodies (Cell Signaling Technology), respectively. See complete
unedited blots in the supplemental material. The insulin ELISA used
detects both mouse and bovine insulin, with 2.1-fold greater sensitivity for bovine insulin than for mouse insulin.
Evaluation of skeletal muscle microvascular function. DCE-US
was performed on the proximal hind limb adductor muscle group
(adductor magnus and semimembranosus) at baseline and toward
the end of a 2-hour hyperinsulinemic-euglycemic clamp entailing
an insulin infusion at 20 mU/Kg/min (46–49). Isoflurane anesthesia
was given, a right jugular vein catheter was placed for infusions, and
the rectal temperature was maintained at 36.5oC ± 0.5oC throughout the procedure using a RightTemp Temperature Monitor and
Homeothermic Controller (Kent Scientific Corp.). Blood glucose
levels were monitored every 5 minutes by glucometer and mainjci.org   Volume 128   Number 1   January 2018
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tained at 120 ± 5 mg/dl. The muscle was imaged in cross-sections
in a plane perpendicular to the major muscle fiber direction using a
Siemens Sequoia ultrasound system equipped with a high-frequency
15L8 transducer. The transducer was mechanically fixed in position to eliminate motion. A microbubble contrast agent–sensitive
imaging mode (cadence pulse sequencing [CPS]) was used with a
transmit frequency of 1.0 MHz. Data were recorded and processed
offline using custom MATLAB software (MathWorks) (50). The lipid shelled perfluorocarbon-based microbubble contrast agent used
was purchased from Advanced Microbubbles Laboratories, and the
median bubble diameter ranged from 1.886 to 2.087 μm. DCE-US
imaging was performed for 10 minutes before and after a 1-minute
controlled i.v. infusion of contrast media (2.5 × 107 microbubbles in
100 μl saline) administered by infusion pump. Regions-of-interest
(ROI) were defined, and average time-intensity curves were generated and analyzed to extract measurements of CBV (Ipk), MBF (Tpk
and WIR), and both CBV and MBF (AUC; and WOR) (46–48, 51).
Human subjects. Adult human subjects who were metabolically healthy (n = 6) or with a previous clinical diagnosis of T2DM (n =
6) were studied. Blood was collected by venipuncture and placed on
ice, and plasma was separated immediately and stored at –80°C until
IgG isolation was performed. Clinical characteristics of the study
subjects are provided in Supplemental Table 1, including their insulin
sensitivity and disposition index measured using an insulin-modified
frequently sampled i.v. GTT and MINMOD modeling (52, 53). At the
time of sampling, 3 of the patients with diabetes were not receiving
antidiabetic medications, 2 patients were taking metformin and insulin, and 1 patient was taking metformin alone.
IgG purification, SNA lectin blotting, and IgG transfer experiments.
Total IgG was purified from mouse or human serum using spin columns (Melon Gel IgG Spin Purification Kit; 45206; Thermo Fisher Scientific). Mouse IgG subclasses IgG1, IgG2b, and IgG2c were separated
as previously described (54). Briefly, purified total IgG was applied to
a HiTrap Protein A HP column (GE Healthcare) with 100 mM sodium
phosphate buffer (pH 8.0), and IgG1, IgG2c, and IgG2b were sequentially eluted with 0.1 M citric acid buffer at pH6.0, pH4.6, and pH3.8,
respectively. The purity of the obtained IgG subclasses was confirmed
by ELISA (Bethyl Laboratories).
Relative IgG sialylation was evaluated by lectin blotting using
SNA (Vector Laboratories), which binds specifically to sialic acid
attached to terminal galactose in α-2-6 linkage. Briefly, IgG was separated by SDS-PAGE and transferred to a PVDF membrane, and the
membrane was incubated in Carbo-Free blocking solution for 30
minutes at room temperature, followed by incubation in PBS containing biotinylated SNA (1 μg/ml) for 18 hours at 4°C. After washing,
biotinylated lectin binding was detected by HRP-linked anti-biotin
antibody (Cell Signaling Technology) and chemiluminescence methods. In studies evaluating the actions of hyposialylated IgG, the terminal sialic acid was removed from the Fc glycan by treatment with
NA. IgG (500 μg) was incubated with 100 units of NA in 0.05 M sodium citrate buffer, pH 6.0, at 37°C for 20 hours. Effective desialylation was confirmed by SNA-lectin blotting. See complete unedited
blots in the supplemental material.
The impact of IgG on glucose homeostasis was determined in
IgG transfer experiments. The recipients were male B–/– mice who had
received a HFD for the previous 12 weeks. While continuing on a HFD,
IgG (150 μg/dose) was administered i.p. twice a week, and individual
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glucose homeostasis readouts (GTT or ITT) were performed 1 week
apart. In select experiments, the recipient B–/– mice were additionally
FcγRIIB–/–, FcγRIIBfl/fl, or FcγRIIBΔEC. The IgGs used included total IgG
isolated from WT or FcγRIIB–/– male mice given control chow versus a
HFD for 12 weeks, total IgG from control chow-fed male mice treated
ex vivo with buffer versus NA prior to administration, and total IgG
isolated from insulin sensitive versus human subjects with T2DM. In
the latter experiment, each individual human IgG sample was administered to 3 to 5 mice, and the values obtained were averaged to yield
a single value per IgG sample. In a control experiment related to the
IgG transfer studies with NA-treated IgG, possible effects on glucose
homeostasis of NA alone, administered at a dose equal to that received
with NA-treated IgG, were evaluated.
Glycoproteomic analysis. Mouse IgG2c samples (0.65–0.70 mg/
ml, control and HFD) were cleaved into Fc and Fab portions by
immobilized papain (Pierce Fab Preparation Kit; Thermo Fisher
Scientific) according to the manufacturer’s protocol. The IgG2c Fc
domain was separated by a protein A–plus spin column, and the eluate was dried by vacuum centrifugation and stored at –80°C until
further analysis. The dried samples were dissolved in 100 μl of
nanopure water, mixed with 2× Laemmli sample buffer (Bio-Rad),
and subjected to SDS-PAGE, and in-gel digestion of IgG by sequencing grade trypsin (Promega) was performed as previously described
(55). The samples underwent nano-liquid chromatography tandem
MS (LC-MS/MS) analysis using Orbitrap Fusion (Thermo Fisher
Scientific) equipped with a Nanospray Flex source with CID, HCD,
and ETD options and a Dionex UltiMate 3000 Autosampler LC
system (Thermo Fisher Scientific). LC separation was performed
on a nanoViper-C18 column using a water/acetonitrile gradient
with formic acid. The MS precursor scan was performed using an
Orbitrap detector at 120,000 Orbitrap resolution in positive mode.
MS/MS fragment ions were analyzed using an Orbitrap detector at
30,000 Orbitrap resolution. The resulting data were initially used
for protein identification, which was achieved by searching a protein database from Mus musculus (mouse, downloaded from UniProt, http://www.uniprot.org/) using the Sequest HT Search Wizard
in the software Proteome Discoverer 1.4 (Thermo Fisher Scientific). Trypsin was selected as the digestion enzyme, specific cleavage
sites (the carboxyl side of lysine and arginine) were enabled, and
up to 2 missed cleavages were allowed. Differential search parameters were allowed for the protein identity check, with carboxyamidomethylation of cysteine as a fixed modification and oxidation of
methionine as a variable modification. The data were subsequently
manually analyzed for glycopeptides using Byonic (Protein Metrics
Inc.) and Xcalibur (Thermo Fisher Scientific) software. The MS/MS
spectra of glycopeptides were screened and evaluated for oxonium
ions, monosaccharide and oligosaccharide neutral loss patterns,
and their peptide backbone fragmentations to determine the existence of glycans in these glycopeptides and the sequence of their
peptide backbones.
Cell culture experiments. Primary BAECs were obtained as previously described (28), primary HAECs were purchased from Lonza,
and cells were used within 5 to 7 passages. To evaluate the requirement
for FcγRIIB in actions of IgG on BAECs, cells were transfected with
siRNA using Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific). Double-stranded (ds) RNA with the sequence 5′-GAAACCAGCCUCUGAAUAAUU-3′ was designed to target the ORF of bovine
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FcγRIIB (GenBank accession number NM_174539), and nontargeting
siRNA was used as a negative control (ON-TARGETplus Nontargeting
siRNA; D-001810-02-20; Dharmacon). Forty-eight hours after transfection, the knockdown of FcγRIIB was evaluated by immunoblotting
using eNOS abundance to assess protein loading. See complete unedited blots in the supplemental material.
In studies of eNOS activation, the conversion of [14C]-L-arginine
14
to [ C]-L-citrulline by intact cells was measured for 15 minutes in the
absence (basal) or presence of insulin (100 μg/ml) (28). Additional
treatments included CRP (25 μg/ml; Sigma-Aldrich), mouse total IgG,
IgG1, IgG2b, or IgG2c, or human total IgG (10 μg/ml) present during
a 30-minute preincubation and also during the 15-minute incubation
for quantification of NOS activity. In select studies, mouse IgG was
treated with vehicle or NA, as described above, before addition to the
cells, and the impact of an equal concentration of NA alone was also
determined as a control.
Endothelial cell insulin transcytosis was studied in HAECs as
previously described (56). Cells were seeded onto Transwell inserts
(6.5-mm diameter, 3-μm pore size, polycarbonate membrane inserts;
Sigma-Aldrich) treated with collagen I (BD Bioscience), and TEER
was monitored 4–5 days later using an epithelial voltohmmeter
(EVOM) (World Precision Instruments) to confirm the establishment
of a confluent monolayer. Vehicle, CRP (25 μg/ml), mouse IgG (10 μg/
ml), L-NAME (2 mM; Sigma-Aldrich), or CRP or mouse IgG plus the
NO donor S-nitroso-N-acetylpenicillamine (100 nM; SNAP; Sigma-
Aldrich) was then added together with FITC-insulin (50 nM; Sigma-
Aldrich) into the upper chamber, and the cells were incubated for 2
hours at 37°C. In a separate set of experiments, vehicle, CRP, or mouse
IgG in the presence of control IgG (10 μg/ml; mouse IgG1; Abcam)
or anti-FcγRIIB–blocking antibody (10 μg/ml; AT10; Abcam) was
placed into the upper chamber along with FITC-insulin. At the end
of the incubation, the FITC-insulin in the lower chamber was quantified using a fluorimeter (POLARstar Omega; BMG LABTECH), and
the percentage of insulin initially placed into the upper chamber that
was transported to the bottom chamber was calculated. FITC-dextran
(molecular weight 4,000; Sigma-Aldrich) was used to assess paracellular transport, and only 3.8% of FITC-dextran (n = 4) added to the
upper chamber was detected in the lower chamber after 2 hours, indicating negligible paracellular molecule transport.
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